Healthcare Industry News: estradiol
News Release - July 10, 2007
Agile Therapeutics Appoints Dr. Marie Foegh as Chief Medical Officer
PRINCETON, N.J., July 10 (HSMN NewsFeed) -- Dr. Marie Foegh has joined Agile Therapeutics, Inc., as Chief Medical Officer. Dr. Foegh brings to Agile's executive management team more than 20 years experience in the pharmaceutical and biotechnology industries. She was most recently Vice President of Medical Affairs, Strategy & Development for Female Health Care at Berlex, Inc., where she was responsible for the successful development and regulatory approval of several new contraceptive products, including Yasmin® and Yaz®. She also managed the approval process for follow-on indications of premenstrual dysphoric disorder, a first in class indication, followed by acne.Agile Therapeutics is an emerging bio-pharmaceutical company focused on developing the next generation of transdermal contraception, a low estrogen dose patch, which is now in Phase II clinical trials. Dr. Foegh will spearhead creation and execution of Agile's clinical strategies as well as lead the development of products, formulations and additional indications.
"We're very excited to have Marie join Agile," said Dr. Thomas Rossi, CEO of Agile Therapeutics. "Her unique experience in the global pharmaceutical industry will be invaluable to our success in developing novel low-estrogen contraceptive products that represent the next generation of patch technology. With Marie on board to direct Clinical Development and Medical Affairs and our recent addition of Lisa Flood as Associate Director of Regulatory and Quality Assurance, Agile now has a very strong balance of expertise in transdermal technology, women's health care, and drug development.
During her tenure at Berlex, Dr. Foegh also focused on R&D for alternative delivery routes in contraception. Prior to joining Berlex, she held senior positions at Solvay Pharmaceuticals US and with the IPSEN Group's Henri Beaufour Institute USA, where she worked on small peptides and their delivery.
Dr. Foegh is a board-certified Ob-Gyn in Scandinavia, trained in Internal Medicine in the US and licensed to practice medicine. She is Adjunct Professor at Georgetown University Medical School's Department of Medicine, Division of Nephrology and Hypertension, and has written more than 150 peer-reviewed publications.
About Agile Therapeutics
Agile Therapeutics is a privately funded women's health company. The Company's lead product is a low estrogen dose seven-day transdermal contraceptive. This unique patch system delivers a combination of levonorgestrel and ethinyl estradiol. Agile's patch is expected to compete effectively in the $5 billion worldwide contraceptive market and is currently in Phase II clinical development. The Company is supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over $875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over $1.4 billion under management; and PA Early Stage Partners, with more than $235 million under management.
Source: Agile Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
